ADMA Biologics, Inc. (ADMA)
US — Healthcare Sector
Automate Your Wheel Strategy on ADMA
With Tiblio's Option Bot, you can configure your own wheel strategy including ADMA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ADMA
- Rev/Share 1.932
- Book/Share 1.5705
- PB 11.296
- Debt/Equity 0.2196
- CurrentRatio 6.5762
- ROIC 0.4874
- MktCap 4235141160.0
- FreeCF/Share 0.3813
- PFCF 46.7161
- PE 20.4
- Debt/Assets 0.1606
- DivYield 0
- ROE 0.7239
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 1
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
ADMA
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
RAMSEY, N.J. and BOCA RATON, Fla.
Read More
Adma Biologics (ADMA) Stock Slides as Market Rises: Facts to Know Before You Trade
ADMA
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Negative
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Negative
Adma Biologics (ADMA) closed the most recent trading day at $16.07, moving -0.62% from the previous trading session.
Read More
Pharma Stock Poised to Bounce Off Support
ADMA
Published: February 12, 2025 by: Schaeffers Research
Sentiment: Positive
Published: February 12, 2025 by: Schaeffers Research
Sentiment: Positive
Pharmaceutical concern ADMA Biologics Inc (NASDAQ:ADMA) has been consolidating above familiar pressure at the $16 region since mid-January.
Read More
About ADMA Biologics, Inc. (ADMA)
- IPO Date 2013-10-17
- Website https://www.admabiologics.com
- Industry Biotechnology
- CEO Mr. Adam S. Grossman
- Employees 685
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.